Kiniksa Pharmaceuticals International plc
Last updated September 27, 2026
Organization details
- Legal name
- Kiniksa Pharmaceuticals International plc
- Ownership
- Public
- Status
- Active
- Headquarters country
- United States
- Ticker symbol
- KNSA
- Primary stock exchange
- Nasdaq
Identifiers
- SEC CIK
- 0001730430
Board of directors
-
Barry D. Quart · DirectorSince 2023
- Since 2023
-
G. Bradley Cole · DirectorSince 2023
- Since 2023
-
Kimberly J. Popovits · DirectorSince 2023
-
Meta Cantey Boyd · DirectorSince 2024
-
Richard S. Levy · DirectorSince 2023
-
Sanj K. Patel · Director · CHAIRMAN & CEOSince 2023
-
Thomas Malley · DirectorSince 2023
-
Tracey L. McCain · DirectorSince 2023
Chief executives
Sanj K. Patel
· CHAIRMAN & CEO
Dates unknown
Board connections
7 of this board's directors also sit on 23 other boards.
- via Felix Baker, Julian Baker and Thomas Malley
- via Felix Baker, Julian Baker and Richard S. Levy
- via Felix Baker, Julian Baker and Richard S. Levy
- via Felix Baker and Julian Baker
- via Felix Baker and Julian Baker
- via Felix Baker and Julian Baker
- via Felix Baker and Julian Baker
- via Felix Baker and Julian Baker
- via Felix Baker and Julian Baker
- via Felix Baker and Julian Baker
- via Felix Baker and Julian Baker
- via Felix Baker and Julian Baker
- via Felix Baker and Julian Baker
- via Felix Baker and Julian Baker
- via Felix Baker and Julian Baker
- via Kimberly J. Popovits
- via G. Bradley Cole
- via Barry D. Quart
- via Barry D. Quart
- via Kimberly J. Popovits
- via Thomas Malley
- via Richard S. Levy
- via Kimberly J. Popovits
Insider trades
All notable trades →From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.
- Bought, last 12 months
- $0
- 0 purchases by 0 insiders
- Sold, last 12 months
- $61,898,754
- 48 sales by 8 insiders
| Date | Insider | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| Sep 3, 2026 | Megna Michael R Officer (CHIEF ACCOUNTING OFFICER) | Open-market sale | −4,600 | $80.30 | $369,380 |
| Sep 1, 2026 | Sanj K. Patel Director, Officer (CHAIRMAN & CEO) | Option exercise | +9,991 | — | — |
| Sep 1, 2026 | Sanj K. Patel Director, Officer (CHAIRMAN & CEO) | Option exercise | +9,991 | — | — |
| Sep 1, 2026 | Paolini John F. Officer (CHIEF MEDICAL OFFICER) | Option exercise | +2,497 | — | — |
| Sep 1, 2026 | Ragosa Mark Officer (CHIEF FINANCIAL OFFICER) | Option exercise | +2,694 | — | — |
| Sep 1, 2026 | Moat Ross Officer (CHIEF OPERATING OFFICER) | Option exercise | +2,477 | — | — |
| Sep 1, 2026 | Megna Michael R Officer (CHIEF ACCOUNTING OFFICER) | Option exercise | +3,932 | — | — |
| Sep 1, 2026 | Sanj K. Patel Director, Officer (CHAIRMAN & CEO) | Option exercise | +6,481 | — | — |
| Sep 1, 2026 | Sanj K. Patel Director, Officer (CHAIRMAN & CEO) | Option exercise | +6,481 | — | — |
| Sep 1, 2026 | Paolini John F. Officer (CHIEF MEDICAL OFFICER) | Option exercise | +1,624 | — | — |
| Sep 1, 2026 | Ragosa Mark Officer (CHIEF FINANCIAL OFFICER) | Option exercise | +1,750 | — | — |
| Sep 1, 2026 | Moat Ross Officer (CHIEF OPERATING OFFICER) | Option exercise | +1,611 | — | — |
| Sep 1, 2026 | Megna Michael R Officer (CHIEF ACCOUNTING OFFICER) | Option exercise | +2,558 | — | — |
| Sep 1, 2026 | Sanj K. Patel Director, Officer (CHAIRMAN & CEO) | Option exercise | +6,237 | — | — |
| Sep 1, 2026 | Sanj K. Patel Director, Officer (CHAIRMAN & CEO) | Option exercise | +6,237 | — | — |
Reviews (0)
Sign in to write a review.
No reviews yet. Be the first to write one.